Literature DB >> 2126634

In vitro capacity of various cyclooxygenase inhibitors to revert immune suppression caused by radiation therapy for breast cancer.

H Blomgren1, S Rotstein, J Wasserman, B Petrini, S Hammarström.   

Abstract

Radiation therapy triggers blood monocytes to an increased secretion of immunosuppressive prostaglandins (PGs), which in part can explain the post-irradiation impairment of lymphocyte blastogenesis. Since low mitogen responses of lymphocytes in irradiated breast cancer patients is linked to a poor prognosis a clinical trial is planned to examine if treatment with inhibitors of PG-synthesis during irradiation can counteract immunosuppression and increase survival. In the present investigation we have compared nine different inhibitors of PG-synthesis for capacity to enhance phytohemagglutinin responses of blood lymphocytes before and after irradiation for breast cancer. Five of the drugs (aspisol, indomethacin, meclofenamic acid, ketoprofen and diclofenac) enhanced the reactivity to more than 150%. In general, the strongest enhancements were observed in lymphocyte preparations obtained at completion of irradiation when reactivity was most depressed followed by those obtained at one month and before irradiation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2126634     DOI: 10.1016/0167-8140(90)90033-s

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  Cyclooxygenase-1 and -2 are expressed by human T cells.

Authors:  J L Pablos; B Santiago; P E Carreira; M Galindo; J J Gomez-Reino
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

Review 2.  Repurposing Drugs for Cancer Radiotherapy: Early Successes and Emerging Opportunities.

Authors:  Mohammad K Khan; Tahseen H Nasti; Zachary S Buchwald; Ralph R Weichselbaum; Stephen J Kron
Journal:  Cancer J       Date:  2019 Mar/Apr       Impact factor: 3.360

3.  Impact of acetylsalicylic Acid on the clinicopathological characteristics and prognosis of patients with invasive breast cancer.

Authors:  Mehmet A N Sendur; Sercan Aksoy; Nuriye Y Ozdemir; Nurullah Zengin; Kadri Altundag
Journal:  Breast Care (Basel)       Date:  2014-04       Impact factor: 2.860

4.  Aspirin intake and survival after breast cancer.

Authors:  Michelle D Holmes; Wendy Y Chen; Lisa Li; Ellen Hertzmark; Donna Spiegelman; Susan E Hankinson
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

5.  Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent.

Authors:  Pan Pantziarka; Vidula Sukhatme; Gauthier Bouche; Lydie Meheus; Vikas P Sukhatme
Journal:  Ecancermedicalscience       Date:  2016-01-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.